MindMed Adds MDMA To Develop Next-Gen Psychedelic Therapies

Mind Medicine (MindMed) Inc., a leading neuro-pharmaceutical company for psychedelic inspired medicines, is now adding the psychedelic compound MDMA to its research and development (R&D) pipeline. The latest development comes as part of MindMed's exclusive license and collaboration agreement with the University Hospital Basel's Liechti Lab. The company will now gain access to a compelling portfolio of clinical trials and studies gathered by the Liechti Lab over a 10 year period on MDMA. This data will now enable MindMed to design compelling clinical trials and form a strategy for MDMA as part of its portfolio . . .